Preview

Эндокринная хирургия

Расширенный поиск

По материалам клинических рекомендаций по ведению больных с дифференцированными нейроэндокринными опухолями илеоеюнальной локализации

https://doi.org/10.14341/2306-3513-2009-1-3-10

Полный текст:

Аннотация

Полный текст рекомендаций: B. Eriksson, G. Kloppel, E. Krennin, H. Ahlman, U. Phckinger, B. Wiedenmann, R. Arnold, C. Auernhammer, M. Когжг, G. Rindi, S. Wildi et al. Neuroendocrinology 2008, 87, р. 8-19

Список литературы

1. B. Eriksson, G. Kloppel, E. Krennin, H. Ahlman, U. Phckinger, B. Wiedenmann, R. Arnold, C. Auernhammer, M. Когжг, G. Rindi, S. Wildi et al. Neuroendocrinology 2008, 87, р. 8-19

2. Modlin IM, Lye KD, Kidd M: A five-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-959.

3. Kulke MH, Mayer RJ: Carcinoid tumors. N Engl J Med 1999; 340: 858-868.

4. Burke AP, Thomas RM, Elsayed AM, Sobin LH: Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. Cancer 1997; 79: 10861093.

5. Peck JJ, Shields AB, Boyden AM, Dworkin LA, Nadal JW: Carcinoid tumors ofthe ileum. Am J Surg 1983; 146: 124-132.

6. Modlin IM, Sandor A: An analysis of 8,305 cases of carcinoid tumors. Cancer 1997; 79: 813-829.

7. Loftus JP, van Heerden JA: Surgical management of gastrointestinal carcinoid tumors. Adv Surg 1995; 28: 317-336.

8. Godwin JD 2nd: Carcinoid tumors. An analysis of 2,837 cases. Cancer 1975; 36: 560569.

9. Solcia E KG, Sobin LH, in collaboration with 9 pathologists from 4 countries: Histological Typing of Endocrine Tumors, ed 2. WHO International Histological Classification of Tumors. Berlin, Springer, 2000.

10. Berge T, Linell F: Carcinoid tumours. Frequency in a defined population during a 12year period. Acta Pathol Microbiol Scand [A] 1976; 84: 322-330.

11. Strodel WE, Talpos G, Eckhauser F, Thompson N: Surgical therapy for small-bowel carcinoid tumors. Arch Surg 1983; 118: 391-397.

12. Marshall JB, Bodnarchuk G: Carcinoid tumors of the gut. Our experience over three decades and review of the literature. J Clin Gastroenterol 1993;16:123-129.

13. McDermott EW, Guduric B, Brennan MF: Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg 1994; 81: 1007-1009.

14. Arnold R, Rinke A, Klose KJ , et al: Octreotide versus octreotide plus interferon_ in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005; 3: 761-771.

15. Oberg K: Chemotherapy and biotherapy in neuroendocrine tumors. Curr Opin Oncol 1993; 5: 110-120.

16. Moertel CG: Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987; 5: 1502-1522.

17. Creutzfeldt W: Carcinoid tumors: development of our knowledge. World J Surg 1996; 20: 126-131.

18. Oberg K: The use of chemotherapy in the management of neuroendocrine tumors. Endocrinol Metab Clin North Am 1993; 22: 941-952.

19. Ahlman H, Westberg G, Wangberg B , et al: Treatment of liver metastases of carcinoid tumors. World J Surg 1996; 20: 196-202.

20. Zuetenhorst JM, Bonfrer JM, Korse CM, Bakker R, van Tinteren H, Taal BG: Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor_ and fibroblast growth factor. Cancer 2003; 97: 1609-1615.

21. Norheim I, Oberg K, Theodorsson-Norheim E , et al: Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 1987; 206: 115-125.

22. Makridis C, Rastad J, Oberg K, Akerstrom G: Progression of metastases and symptom improvement from laparotomy in midgut carcinoid tumors. World J Surg 1996; 20: 900907.

23. Westberg G, Wangberg B, Ahlman H, Bergh CH, Beckman-Suurkula M, Caidahl K: Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome. Br J Surg 2001; 88: 865-872.

24. Krenning EP, Kwekkeboom DJ, Bakker WH , et al: Somatostatin receptor scintigraphy with [ 111 In-DTPAD -Phe 1 ]and [ 123 I-Tyr 3 ]-octreotide: the Rotterdam experience with more than 1,000 patients. Eur J Nucl Med 1993; 20: 716-731.

25. Hofmann M, Maecke H, Borner R , et al: Biokinetics and imaging with the somatostatin receptor PET radioligand 68 Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001; 28: 1751-1757.

26. Ricke J, Klose KJ, Mignon M, Oberg K, Wiedenmann B: Standardisation of imaging in neuroendocrine tumours: results of a European delphi process. Eur J Radiol 2001; 37: 8-17.

27. Kaltsas G, Rockall A, Papadogias D, Reznek R, Grossman AB: Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol 2004; 151: 15-27.

28. Bader TR, Semelka RC, Chiu VC, Armao DM, Woosley JT: MRI of carcinoid tumors: spectrum of appearances in the gastrointestinal tract and liver. J Magn Reson Imaging 2001; 14: 261-269.

29. Orlefors H, Sundin A, Garske U , et al: Wholebody 11 C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005; 90: 3392-3400.

30. Koopmans KP, de Vries EG, Kema IP , et al: Staging of carcinoid tumours with 18 F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol 2006; 7: 728-734.

31. Van Tuyl SA, van Noorden JT, Timmer R, Stolk MF, Kuipers EJ, Taal BG: Detection of small-bowel neuroendocrine tumors by video capsule endoscopy. Gastrointest Endosc 2006; 64: 66-72.

32. Swain P: Wireless capsule endoscopy. Gut 2003; 52(suppl 4):48-50.

33. Oberg K, Stridsberg M: Chromogranins as diagnostic and prognostic markers in neuroendocrine tumours. Adv Exp Med Biol 2000; 482: 329-337.

34. Ardill JE, Erikkson B: The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut. Endocr Relat Cancer 2003; 10: 459-462.

35. Feldman JM, O'Dorisio TM: Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med 1986; 81: 41-48.

36. Eriksson B, Oberg K: Peptide hormones as tumor markers in neuroendocrine gastrointestinal tumors. Acta Oncol 1991; 30: 477483.

37. Hamilton SR AL: Tumors of the digestive system. Pathology and Genetics. WHO Classification of Tumours. Lyon, ARC Press, 2000.

38. Rindi G, Kloppel G, Alhman H , et al: TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449: 395-401.

39. Hemminki K, Li X: Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 2001; 92: 2204-2210.

40. Hemminki K, Li X: Familial carcinoid tumors and subsequent cancers: a nationwide epidemiologic study from Sweden. Int J Cancer 2001; 94: 444-448.

41. Akerstrom G, Makridis C, Johansson H: Abdominal surgery in patients with midgut carcinoid tumors. Acta Oncol 1991; 30: 547-553.

42. Rothmund M, Kisker O: Surgical treatment of carcinoid tumors of the small bowel, appendix, colon and rectum. Digestion 1994; 55(suppl 3):86-91.

43. Ahlman H, Wangberg B, Jansson S , et al: Interventional treatment of gastrointestinal neuroendocrine tumours. Digestion 2000; 62(suppl 1):59-68.

44. Makridis C, Oberg K, Juhlin C , et al: Surgical treatment of mid-gut carcinoid tumors. World J Surg 1990; 14: 377-384.

45. Norton JA: Surgical management of carcinoid tumors: role of debulking and surgery for patients with advanced disease. Digestion 1994; 55(suppl 3):98-103.

46. Goede AC, Winslet MC: Surgery for carcinoid tumours of the lower gastrointestinal tract. Colorectal Dis 2003; 5: 123-128.

47. Frilling A, Rogiers X, Malago M, Liedke OM,Kaun M, Broelsch CE: Treatment of liver metastases in patients with neuroendocrine tumors. Langenbecks Arch Surg 1998; 383: 6270.

48. Lehnert T, Knaebel HP: Diagnosis and therapy of liver metastases of neuroendocrine tumors in German). hirurg 1997; 68: 122131.

49. Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA: Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1998; 187: 8893.

50. Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK: Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995; 169: 36^3.

51. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG: Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003; 197: 29-37.

52. Chamberlain RS, Canes D, Brown KT , et al: Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000; 190: 432-445.

53. Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT: Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 2003; 134: 1057-1065.

54. Soreide O, Berstad T, Bakka A , et al: Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors. Surgery 1992; 111: 48-54.

55. Moertel CG, Sauer WG, Dockerty MB, Baggenstoss AH: Life history ofthe carcinoid tumor ofthe small intestine. Cancer 1961; 14: 901-912.

56. Dousset B, Saint-Marc O, Pitre J, Soubrane O, Houssin D, Chapuis Y: Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg 1996; 20: 908-915.

57. Chung MH, Pisegna J, Spirt M , et al: Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 2001; 130: 954-962.

58. Wangberg B, Westberg G, Tylen U , et al: Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction.World JSurg 1996;20:892-899.

59. McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS: Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990; 108: 1091-1096.

60. Eriksson B, Oberg K: Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol 1999; 10(suppl 2):S31-S38.

61. Eriksson B, Renstrup J, Imam H, Oberg K: High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 1997; 8: 1041-1044.

62. Wymenga AN, Eriksson B, Salmela PI , et al: Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 1999; 17: 1111.

63. Ducreux M, Ruszniewski P, Chayvialle JA , et ак The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000; 95: 3276-3281.

64. Di Bartolomeo M, Bajetta E, Buzzoni R , et al: Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medi cal Oncology Group. Cancer 1996; 77: 402408.

65. Arnold R, Trautmann ME, Creutzfeldt W , et al: Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996; 38: 430-438.

66. Aparicio T, Ducreux M, Baudin E , et al: Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001; 37: 10141019.

67. O'Toole D, Ducreux M, Bommelaer G , et al:Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000; 88: 770-776.

68. Ruszniewski P, Ducreux M, Chayvialle JA , et al: Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 1996; 39: 279-283.

69. Tomassetti P, Migliori M, Gullo L: Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol 1998; 93: 1468-1471.

70. Tomassetti P, Migliori M, Corinaldesi R, Gullo L: Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther 2000; 14: 557-560.

71. Faiss S, Pape UF, Bohmig M , et al: Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors The International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21: 2689-2696.

72. Rubin J, Ajani J, Schirmer W , et al: Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999; 17: 600-606.

73. Ricci S, Antonuzzo A, Galli L , et al: Octreotide аcetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol 2000; 11: 1127-1130.

74. Leong WL, Pasieka JL: Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature. J Surg Oncol 2002; 79: 180187.

75. Saltz L, Trochanowski B, Buckley M , et al:Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 1993; 72: 244-248.

76. Plockinger U, Dienemann D, Quabbe HJ: Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly. J Clin Endocrinol Metab 1990; 71: 16581662.


Для цитирования:


., . По материалам клинических рекомендаций по ведению больных с дифференцированными нейроэндокринными опухолями илеоеюнальной локализации. Эндокринная хирургия. 2009;3(1):3-10. https://doi.org/10.14341/2306-3513-2009-1-3-10

For citation:


Bel'tsevich D.G., Mel'nichenko G.A. Po materialam klinicheskikh rekomendatsiy po vedeniyu bol'nykh s differentsirovannymi neyroendokrinnymi opukholyami ileoeyunal'noy lokalizatsii. Endocrine Surgery. 2009;3(1):3-10. (In Russ.) https://doi.org/10.14341/2306-3513-2009-1-3-10

Просмотров: 20


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2306-3513 (Print)
ISSN 2310-3965 (Online)